The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
The low-risk papillomaviruses
Open accessAbstract
Human Papillomavirus (HPV) research has been dominated by the study of a subset of Alpha papillomaviruses that together cause almost 5% of human cancers worldwide, with the focus being on the two most prominent of these (HPV16 and 18). These viruses are referred to as 'high-risk' (hrHPV), to distinguish them from the over 200 prevalent HPV types that more commonly cause only benign epithelial lesions. The 'low-risk' (lrHPV) term used to describe this group belies their cumulative morbidity. Persistent laryngeal papillomas, which occur rarely in children and adults, require regular surgical de-bulking to allow breathing. Such infections are not curable, and despite being caused by HPV11 (a lrHPV) are associated with 1-3% risk of cancer progression if not resolved. Similarly, the ubiquitous Beta HPV types, which commonly cause asymptomatic infections at cutaneous sites, can sometimes cause debilitating papillomatosis with associated cancer risk. Recalcitrant genital warts, which affect 1 in 200 young adults in the general population, and even the ubiquitous common warts and verrucas that most of us at some time experience, cannot be reliably eradicated, with treatment strategies advancing little over the last 100 years. The review highlights molecular similarities between high and low-risk HPV types, and focuses on the different pathways that the two groups use to ensure persistent infection and adequate virus shedding from the epithelial surface. Understanding the normal patterns of viral gene expression that underlie lesion formation, and which also prevent loss of the infected basal cells in established lesions, are particularly important when considering new treatment options. Finally, the common requirement for deregulated viral gene expression and genome persistence in development of cancers, unites both high and low-risk HPV types, and when considered alongside viral protein functions, provides us with a working understanding of the mechanisms that underlie HPV-associated pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jackson, S., & Storey, A. (2000) · Oncogene · doi:10.1038/sj.onc.1203339 · Cited by 190
RetractedClassification of papillomaviruses
de Villiers, E.-M., Fauquet, C., Broker, T. R., Bernard, H.-U., & zur Hausen, H. (2004) · Virology · doi:10.1016/j.virol.2004.03.033 · Cited by 3,193
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
Bernard, H.-U., Burk, R. D., Chen, Z., van Doorslaer, K., Hausen, H. Z., & de Villiers, E.-M. (2010) · Virology · doi:10.1016/j.virol.2010.02.002 · Cited by 1,669
Papillomaviruses in the causation of human cancers - a brief historical account
zur Hausen, H. (2009) · Virology · doi:10.1016/j.virol.2008.11.046 · Cited by 1,532
The Biology and Life-Cycle of Human Papillomaviruses
Doorbar, J., Quint, W., Banks, L., Bravo, I. G., Stoler, M., Broker, T. R., & Stanley, M. A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.083 · Cited by 1,528
Self-citationLi, N., Franceschi, S., Howell‐Jones, R., Snijders, P. J. F., & Clifford, G. M. (2011) · International Journal of Cancer · doi:10.1002/ijc.25396 · Cited by 1,066
Human papillomavirus molecular biology and disease association
Doorbar, J., Egawa, N., Griffin, H., Kranjec, C., & Murakami, I. (2015) · Reviews in Medical Virology · doi:10.1002/rmv.1822 · Cited by 941
Self-citationDrolet, M., Bénard, É., Boily, M.-C., Ali, H., Baandrup, L., Bauer, H., Beddows, S., Brisson, J., Brotherton, J. M. L., Cummings, T., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71073-4 · Cited by 642
Immune responses to human papillomavirus
Stanley, M. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.09.002 · Cited by 586
Geha, R. S., Notarangelo, L. D., Casanova, J.-L., Chapel, H., Conley, M. E., Fischer, A., Hammarström, L., Nonoyama, S., Ochs, H. D., Puck, J. M., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.08.053 · Cited by 557
Cited by
Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
Pal, A., & Kundu, R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03116 · Cited by 597
The natural history of human papillomavirus infection
de Sanjosé, S., Brotons, M., & Pavón, M. A. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2017.08.015 · Cited by 589
Human papillomaviruses: diversity, infection and host interactions
McBride, A. A. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00617-5 · Cited by 369
Yeo-Teh, N. S. L., Ito, Y., & Jha, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061706 · Cited by 273
Key Molecular Events in Cervical Cancer Development
Balasubramaniam, S. D., Balakrishnan, V., Oon, C. E., & Kaur, G. (2019) · Medicina · doi:10.3390/medicina55070384 · Cited by 263
Metadata
- Authors
- Egawa, N., & Doorbar, J.
- Venue
- Virus Research
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 231
- Pages
- 119-127
- ISSN
- 0168-1702 (ISSN-L)
- OpenAlex
- W2565448904
- Cited by
- 330
- References
- 89
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The low-risk papillomaviruses. https://app.cochat.ai/papers/10.1016/j.virusres.2016.12.017
- The paper
- Egawa, N., & Doorbar, J. (2017). The low-risk papillomaviruses. Virus Research. https://doi.org/10.1016/j.virusres.2016.12.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.